Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del | Zendy

Jennifer L. TaylorCousar | Zendy; À. Munck | Zendy; Edward F. McKone | Zendy; Cornelis K. van der Ent | Zendy; Alexander Mœller | Zendy; C Simard | Zendy; Linda T. Wang | Zendy; Edward P. Ingenito | Zendy; Charlotte McKee | Zendy; Yimeng Lu | Zendy; Julie Lekstrom-Himes | Zendy; J.S. Elborn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Author(s) -

Jennifer L. TaylorCousar,

À. Munck,

Edward F. McKone,

Cornelis K. van der Ent,

Alexander Mœller,

C Simard,

Linda T. Wang,

Edward P. Ingenito,

Charlotte McKee,

Yimeng Lu,

Julie Lekstrom-Himes,

J.S. Elborn

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1709846

Subject(s) - ivacaftor , medicine , cystic fibrosis , placebo , clinical endpoint , randomization , cystic fibrosis transmembrane conductance regulator , randomized controlled trial , pathology , alternative medicine

Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX-661) and ivacaftor (VX-770) was designed to target the underlying cause of disease in patients with cystic fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research